Heterocyclic Chemistry for Cancer and CNS Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (28 February 2019)
Special Issue Editor
Interests: microwave-assisted organic chemistry and scale-up; “Store Operated Calcium Entry” inhibitors (Orai1) for cancer via Délikine program inhibitors; mitochondrial ion channel inhibitors for cancer; protein kinase (PKs) inhibitors for CNS (Alzheimer’s disease and Down syndrome) via Leucettine program inhibitors; fluorescence probes for studies of molecular mechanisms in cancer biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Heterocycles are prevalent in nature and they have the ability to engage in a wide variety of intermolecular interactions and in biochemical processes; consequently, they plays an important role in anti-cancer drug design (65% of the anti-cancer drugs that have received approval from the Food and Drug Administration (FDA) between 2010 and 2015 contain nitrogen-based heterocycles). New heterocyclic compounds have also been developed in the last ten years for the central nervous system (CNS), particularly for the treatment of Alzheimer's disease (AD). Molecular design for the development of cholinesterase (ChEIs) inhibitors, monoaminoxydases (MAOs) inhibitors, NMDA receptor antagonism, etc., involved the exploration of many natural products (their modified derivatives) and also synthetic heterocyclic compounds.
The purpose of the present Special Issue is to present the latest advances in the field of heterocyclic chemistry, used for possible pharmacological applications in cancer and CNS diseases (dementia, epilepsy, headache disorders, Parkinson's disease (PD), stroke and AD).
Prof. Jean-Pierre Bazureau
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heterocycles
- cancer
- tumoral cells
- central nervous system
- cholinesterase inhibitors
- monoaminoxydases inhibitors
- NMDA receptor antagonism
- Alzheimer's disease
- Parkinson's disease
- Stroke
- epilepsy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
